**Background**
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are widespread human pathogens that cause a variety of mucosal and cutaneous infections. These viruses are characterized by their ability to establish lifelong latent infections in sensory ganglia, leading to periodic reactivations. The development of selective antiviral agents that can inhibit viral replication without inducing significant toxicity to host cells is critical for managing these infections and preventing associated complications. In this context, we will introduce a potent and selective anti-herpesvirus agent – Penciclovir.
**Definition**
Penciclovir is a selective anti-herpesvirus agent that exhibits potent activity against HSV-1 and HSV-2, with $\text{EC}_{50}$ values of 0.5 $\mu\text{g/ml}$ and 0.8 $\mu\text{g/ml}$, respectively.
**In Vitro and In Vivo Studies**
The Penciclovir description highlights its broad spectrum of activity against various herpesviruses. In terms of Penciclovir in vitro activity, the compound (0-100 $\mu\text{g/ml}$) demonstrated $\text{EC}_{50}$ values of 0.5 $\mu\text{g/ml}$ for HSV-1 (HFEM), 0.8 $\mu\text{g/ml}$ for HSV-2 (MS), 2.4 $\mu\text{g/ml}$ for VZV (Ellen), and 1.2 $\mu\text{g/ml}$ for BHV-2 (New York 1). It also showed activity against EHV-1 (1.6 $\mu\text{g/ml}$) and FHV-1 (0.9 $\mu\text{g/ml}$), while remaining inactive against SVV ($>100 \mu\text{g/ml}$). Furthermore, Penciclovir exhibits a favorable safety profile; cytotoxicity assays across multiple human cell lines, including MRC-5, WI-38, and HEp-2, showed no toxicity with $\text{IC}_{50}$ values generally exceeding 100 $\mu\text{g/ml}$. Additional studies in HepG2.2.15 cells indicated an $\text{EC}_{50}$ of 3.4 $\mu\text{M}$ for reducing Hepatitis B virus DNA levels.
Regarding Penciclovir In Vivo efficacy, studies using three-week-old female Balb/c mice demonstrated that administration of Penciclovir (100 mg/kg; s.c.; daily for 5 days) effectively prevented mortality. This treatment resulted in reduced virus titers in the respiratory organs of both wild-type and PR3-infected mice. For researchers seeking detailed Penciclovir technical information, these results underscore the compound’s potential as a therapeutic lead. In conclusion, Penciclovir is a potent, non-toxic anti-herpesvirus agent with significant activity across multiple herpesvirus strains.
Keywords
Penciclovir, 39809-25-1, BRL 39123, VSA 671, BRL39123, BRL-39123, VSA671, VSA-671, HSV, Herpes simplex virus, anti-herpesvirus, no-toxic, mortality, Inhibitor
References
[1] M.R. Boyd, et al. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chemistry and Chemotherapy, 1993, (1): 3-11.
[2] de la Fuente R, et al. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antiviral Res. 1992 May;18(1):77-89.